V
VentriNaya develops off-the-shelf regenerative gene and cell therapy platforms to treat cardiovascular diseases, focusing on preventing rehospitalization in heart failure patients. The company utilizes two primary approaches: Cyclin A2 gene therapy (VN-100) and placental CDX2+ stem cell therapy (VN-101) to regenerate injured hearts post-myocardial infarction. These single-dose solutions aim to provide long-term efficacy aligned with payer priorities.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- VentriNaya develops off-the-shelf regenerative gene and cell therapy platforms to treat cardiovascular diseases, focusing on preventing rehospitalization in heart failure patients. The company utilizes two primary approaches: Cyclin A2 gene therapy (VN-100) and placental CDX2+ stem cell therapy (VN-101) to regenerate injured hearts post-myocardial infarction. These single-dose solutions aim to provide long-term efficacy aligned with payer priorities.